Treatment of CLB-BAR cells with lorlatinib further confirmed that ALK signaling regulates SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 protein levels in ALK-addicted NB cell lines (Fig. 6F, Sup. The gene discussed is SLC7A5; the disease is neuroblastoma.